Liposomal amphotericin B prophylaxis of invasive mold infections in children post allogeneic stem cell transplantation

Pediatric Blood and Cancer

Volumn 50, Issue 2, 2008, Pages 325-330

  Roman, Elizabeth ^a   Osunkwo, Ifeyinwa ^b   Militano, Olga ^c   Cooney, Erin ^a   Van De Ven, Carmella ^a   Cairo, Mitchell S ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b EMORY UNIVERSITY   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

AlloSCT; Liposomal amphotericin B; Mold prophylaxis; Pediatrics

Indexed keywords

ALEMTUZUMAB; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPHENHYDRAMINE; ETOPOFOS; FLUDARABINE; FOSCARNET; GANCICLOVIR; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPERGILLUS; BONE MARROW; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HERPES SIMPLEX; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; INCIDENCE; INVASIVE MOLD INFECTION; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MYCOSIS; MYELOABLATIVE CONDITIONING; NEPHROTOXICITY; NEWBORN; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; PILOT STUDY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROBABILITY; PROPHYLAXIS; REDUCED INTENSITY CONDITIONING; RISK ASSESSMENT; SIDE EFFECT; TREATMENT DURATION; UMBILICAL CORD BLOOD;

ADOLESCENT; ADULT; AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; CHILD; CHILD, PRESCHOOL; FEMALE; HEMATOLOGIC DISEASES; HUMANS; INFANT; MALE; MYCOSES; POSTOPERATIVE COMPLICATIONS; STEM CELL TRANSPLANTATION;

EID: 37549006408     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21239     Document Type: Article

References (35)

1. Wingard JR. Fungal infections after bone marrow transplant. Biol Blood Marrow Transplant 1999;5:55-68.
2. Jantunen E, Anttila VJ, Ruutu T. Aspergillus infections in allogeneic stem cell transplant recipients: Have we made any progress? Bone Marrow Transplant 2002;30:925-929.
3. Jantunen E, Ruutu P, Niskanen L, et al. Incidence and risk factors for invasive fungal infections in allogeneic bmt recipients. Bone Marrow Transplant 1997;19:801-808.
4. Wald A, Leisenring W, van Burik JA, et al. Epidemiology of aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997;175:1459-1466.
5. Baddley JW, Stroud TP, Salzman D, et al. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001;32:1319-1324.
6. Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34:909-917.
7. Daly A, McAfee S, Dey B, et al. Nonmyeloablative bone marrow transplantation: Infectious complications in 65 recipients of hla-identical and mismatched transplants. Biol Blood Marrow Transplant 2003;9:373-382.
8. Junghanss C, Marr KA. Infectious risks and outcomes after stem cell transplantation: Are nonmyeloablative transplants changing the picture? Curr Opin Infect Dis 2002;15:347-353.
9. Fukuda T, Boeckh M, Carter RA, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003;102:827-833.
10. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995;171:1545-1552.
11. Marr KA. Antifungal prophylaxis in hematopoietic stem cell transplant recipients. Curr Opin Infect Dis 2001;14:423-426.
12. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin b for empirical therapy in patients with persistent fever and neutropenia. National institute of allergy and infectious diseases mycoses study group. N Engl J Med 1999;340:764-771.
13. Mattiuzzi GN, Estey E, Raad I, et al. Liposomal amphotericin b versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. Cancer 2003;97:450-456.
14. Marr KA, Bowden RA. Fungal infections in patients undergoing blood and marrow transplantation. Transpl Infect Dis 1999;1:237-246.
15. National Cancer Institute Common Terminology Criteria for Adverse Events V.3 (CTCAE) (http://clep.cancer.gov/reporting/CTCAE.html.) In.
16. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002;34:7-14.
17. Shereck E, Bessmertny O, Cooney E, et al. Cytomegalovirus (cmv) prophylaxis with alternate day ganciclovir/foscarnet in at risk pediatric allogeneic stem cell transplant (allosct) recipients is 100% effective in preventing cmv infections and reducing ganciclovir hematopoetic toxicity. Blood (abstract) 2002;100:627a.
18. Osunkwo I, Bessmertny O, Harrison L, et al. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients. Biol Blood Marrow Transplant 2004;10:246-258.
19. Del Toro G, Satwani P, Harrison L, et al. A pilot study of reduced intensity conditioning and allogeneic stem cell transplantation from unrelated cord blood and matched family donors in children and adolescent recipients. Bone Marrow Transplant 2004;33:613-622.
20. Przepiorka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute gvhd grading. Bone Marrow Transplant 1995;15:825-828.
21. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003;9:215-233.
22. el-Ebiary M, Torres A, Fabregas N, et al. Significance of the isolation of candida species from respiratory samples in critically ill, non-neutropenic patients. An immediate postmortem histologic study. Am J Respir Crit Care Med 1997;156:583-590.
23. Barenfanger J, Arakere P, Cruz RD, et al. Improved outcomes associated with limiting identification of candida spp. In respiratory secretions. J Clin Microbiol 2003;41:5645-5649.
24. Abu-Ghosh A, Goldman S, Slone V, et al. Immunological reconstitution and correlation of circulating serum inflammatory mediators/cytokines with the incidence of acute graft-versus-host disease during the first 100 days following unrelated umbilical cord blood transplantation. Bone Marrow Transplant 1999;24:535-544.
25. Cairo MS, Wagner JE. Placental and/or umbilical cord blood: An alternative source of hematopoietic stem cells for transplantation. Blood 1997;90:4665-4678.
26. Hale GA, Bowman LC, Woodard JP, et al. Allogeneic bone marrow transplantation for children with histiocytic disorders: Use of tbi and omission of etoposide in the conditioning regimen. Bone Marrow Transplant 2003;31: 981-986.
27. Iannone R, Casella JF, Fuchs EJ, et al. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transplant 2003;9:519-528.
28. Grewal SS, Krivit W, Defor TE, et al. Outcome of second hematopoietic cell transplantation in hurler syndrome. Bone Marrow Transplant 2002;29:491-496.
29. Branch RA. Prevention of amphotericin b-induced renal impairment. A review on the use of sodium supplementation. Arch Intern Med 1988;148:2389-2394.
30. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin b lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26:1383-1396.
31. Fischer MA, Winkelmayer WC, Rubin RH, et al. The hepatotoxicity of antifungal medications in bone marrow transplant recipients. Clin Infect Dis 2005;41:301-307.
32. Ambisome (Amphotericin B) liposome for injection product monograph (http://www.ambisome.com/index2.php?section=about&page= monograph#pharmacology). Deerfield, IL.
33. Kelsey SM, Goldman JM, McCann S, et al. Liposomal amphotericin (ambisome) in the prophylaxis of fungal infections in neutropenic patients: A randomised, double-blind, placebo-controlled study. Bone Marrow Transplant 1999;23:163-168.
34. Tollemar J, Ringden O, Andersson S, et al. Prophylactic use of liposomal amphotericin b (ambisome) against fungal infections: A randomized trial in bone marrow transplant recipients. Transplant Proc 1993;25:1495-1497.
35. Mehta P, Vinks A, Filipovich A, et al. High-dose weekly ambisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: A pharmacokinetic study. Biol Blood Marrow Transplant 2006;12:235-240.